Cambridge Enterprise Limited

Astrazeneca Ab

David Robert Spring

Jeremy Stephen Parker

Paul Brear

Paul Glossop

Stephen James Walsh

Marko Juhana Hyvonen

Hannah Fiona Sore

A conjugate comprising a protein or a peptide, a linker and an active agent, wherein the linker comprises the moiety of formula (III): (III) wherein two of A, Aand Aare N and the other of A, Aand Ais CH; X is selected from N, O and S, and Pep indicates where the moiety is linked to the protein or peptide, either directly or indirectly.

Linkers and conjugates

Provided are a compound of the formula: (5-(2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethoxy)benzo[c][2,6]naphthyridine-8-carboxylic acid) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the above compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof

Growing community of inventors

Cambridgeshire, United Kingdom

David Robert Spring